Merck offers to pay for additional disease-modifying therapies required during Mavenclad therapy for MS in NICE discussions – sources
Merck KGaA (ETR:MRK) has offered to pay for any additional disease-modifying therapies that multiple sclerosis (MS) patients may require during Mavenclad (cladribine) therapy, as part of ongoing reimbursement discussions with the UK’s National Institute for Health and Care Excellence (NICE), according to two sources familiar with the situation.
Mavenclad, which was approved on 25 August 2017 in Europe, is administered in two courses, 12 months apart, and in clinical trials no additional therapy was required in years three and four. One analyst report notes potential peak sales of EUR 350m in Europe alone.
The two sources noted that if during that two-year course, patients continue to have disease activity which requires an active intervention, then Merck has offered to pay the cost of the additional therapy. The first source noted that this covers both generic and branded MS medication. Both sources noted it was an unusual scheme that has not been employed regularly in the UK, however, it demonstrates the company’s confidence in the medication. This model acts as a risk-sharing agreement and provides a known cost and budget impact to the National Health Service which aligns with new budget impact rules, the first source said.